Akoya BioSciences, Inc. - AKYA STOCK NEWS

Akoya Biosciences and Acrivon Therapeutics announced a partnership to co-develop the innovative OncoSignature test, designed to identify cancer patients most likely to respond to ACR-368, a targeted oncology agent in Phase 2 trials. ACR-368 aims to treat ovarian, endometrial, and urothelial cancers, with promising results in platinum-resistant ovarian cancer. The OncoSignature will utilize Akoya’s PhenoImager technology for patient selection to enhance treatment outcomes, pending ACR-368's approval.

Akoya Biosciences (Nasdaq: AKYA) is set to unveil data from its PhenoCycler-Fusion system, which integrates RNA chemistry for whole-slide spatial multiomics at single-cell resolution, at the AGBT conference in Orlando, Florida, from June 6 to 9, 2022. This advancement complements existing spatial proteomics capabilities, enabling comprehensive multiomic analyses on single tissue samples, crucial for understanding disease progression. CEO Brian McKelligon emphasized that this innovation represents a significant advance in spatial biology.

Akoya Biosciences reported a Q1 2022 revenue of $16.9 million, marking a 38% growth year-over-year. Product revenue reached $13.3 million with a 34% increase, while reagent revenue surged 82% to $4.6 million. Gross profit stood at $10.1 million, a 36% increase, with a gross profit margin of 60%. The company raised its FY 2022 revenue guidance to $70-73 million. Key highlights include the launch of the PhenoCycler-Fusion System and the addition of Dr. Ehab El-Gabry as Chief Medical Officer. Akoya has $94 million in cash reserves as of March 31, 2022.

Akoya Biosciences (Nasdaq: AKYA) announces participation in three key investor conferences. The company will present at the Bank of America 2022 Healthcare Conference on May 10, 2022, at 10:40 AM PT, followed by a fireside chat at the UBS Global Life Science Conference on May 23, 2022, at 7:45 AM ET. Additionally, Akoya will have a virtual presentation available on-demand from May 24-26, 2022, during the HC Wainwright Global Investment Conference. Archived webcasts can be accessed on Akoya’s website.

Akoya Biosciences (Nasdaq: AKYA) has appointed Dr. Ehab A. El-Gabry as Chief Medical Officer to enhance its spatial phenotyping solutions in clinical settings. Dr. El-Gabry, a board-certified pathologist with extensive experience, previously led significant advancements at Roche Tissue Diagnostics. His leadership aims to advance Akoya's translational research strategy and improve patient care through innovative diagnostics. CEO Brian McKelligon highlighted Dr. El-Gabry's invaluable expertise during a pivotal time for the company’s growth in the spatial biology sector.

Akoya Biosciences, Inc. (Nasdaq: AKYA) announced the release of its first-quarter 2022 financial results scheduled for May 5, 2022, post-market close. A conference call will follow at 5:00 p.m. ET to discuss these results. Investors can join the call by calling designated numbers or through a live webcast available on the Akoya website. The company focuses on spatial phenotyping solutions for research, impacting disease progression understanding and therapy response.

Akoya Biosciences (Nasdaq: AKYA) is set to present groundbreaking advancements in spatial phenotyping at the AACR 2022 Annual Meeting from April 8 to 13 in New Orleans. The company will unveil the first 100-plex dataset for deep spatial phenotyping at single-cell resolution and showcase a novel universal chemistry aimed at accelerating biomarker validation. The PhenoCycler™-Fusion's high-speed imaging capabilities will facilitate significant insights into tumor-immune biology, while its file compression technology will streamline data management for researchers. These innovations underscore Akoya’s commitment to enhancing cancer research.

Akoya Biosciences, Inc. (Nasdaq: AKYA) reported a solid Q4 2021, with revenues of $16.2 million, a 26% increase from Q4 2020. For FY 2021, it recorded $54.9 million in revenue, marking a 29.5% growth year-over-year. The company saw strong adoption of its spatial biology solutions, growing its installed base to 697 instruments and achieving 278 publications featuring its platforms. Akoya forecasts FY 2022 revenue between $69-71 million. Furthermore, notable partnerships and launches, including the PhenoCycler™-Fusion System, were announced.

Akoya Biosciences (Nasdaq: AKYA) will release its fourth-quarter and full-year 2021 financial results on March 14, 2022, after market close. Management will discuss the results during a conference call at 5:00 p.m. ET. Interested investors can join the call by dialing designated numbers or via a live webcast on the Akoya website. Additionally, Akoya will participate in the Cowen Annual Health Care Conference on March 8, 2022, at 9:50 a.m. ET, where CEO Brian McKelligon and CFO Joe Driscoll will present.